April 2020, Drugs Monitor, Page 3

(6 April 2020) Tocilizumab- repeat doses for management of Cytokine storm in critically ill patients

April 22, 2020

Tocilizumab treatment in COVID‐19: A single center experience https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25801 In the present study, authors discuss the treatment response of Tocilizumab (TCZ) therapy in COVID‐19 infected patients. The demographic, treatment, laboratory parameters of C‐reactive protein (CRP) and IL‐6 before and after… Continue reading "(6 April 2020) Tocilizumab- repeat doses for management of Cytokine storm in critically ill patients"

(18 March 2020) Lopinavir+Ritonavir- Early clinical outcomes

April 21, 2020

Lopinavir+ Ritonavir- Secondary outcomes of study show some benefits https://www.nejm.org/doi/full/10.1056/NEJMoa2001282 Cao et al. carried out a randomized, controlled, open-label trial for lopinavir–ritonavir (ritonavir helps to stabilize lopinavir) in 199 hospitalized patients with severe COVID-19, of whom 99 were assigned to… Continue reading "(18 March 2020) Lopinavir+Ritonavir- Early clinical outcomes"

(5 April 2020) Favipiravir: Check for DDIs due to AO inhibition

April 21, 2020

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32246834 Favipiravir provides a substitute for compassionate use in COVID-19 based on its mechanism of action inhibiting virus RdRp and safety data in previous clinical studies. Data obtained from influenza… Continue reading "(5 April 2020) Favipiravir: Check for DDIs due to AO inhibition"

(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies

April 21, 2020

Ivermectin- inhibits the replication of SARS-CoV-2 in vitro https://www.sciencedirect.com/science/article/pii/S0166354220302011 Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activityin vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection… Continue reading "(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies"

(05 March 2020) Camostat mesylate- blocks TMPRSS2 activity, which prevents virus entry into host

April 21, 2020

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes)#secsectitle0035 TMPRSS2 is dispensable for development and homeostasis (Kim et al., 2006) and thus constitutes an attractive drug target. In this context, it… Continue reading "(05 March 2020) Camostat mesylate- blocks TMPRSS2 activity, which prevents virus entry into host"

Month: April 2020

(6 April 2020) Tocilizumab- repeat doses for management of Cytokine storm in critically ill patients

(18 March 2020) Lopinavir+Ritonavir- Early clinical outcomes

(5 April 2020) Favipiravir: Check for DDIs due to AO inhibition

(03 April 2020) Ivermectin- 5000 fold reduction in viral RNA at 48h during in-vitro studies

(05 March 2020) Camostat mesylate- blocks TMPRSS2 activity, which prevents virus entry into host